Deborah Ann Miller

CLO Deborah Ann Miller sold 5,500 shares at $107.84 avg for $593.1K via scheduled 10b5-1 plan on 2026-05-28

Deborah Ann Miller, Chief Legal Officer, executed 4 separate sales totaling 5,500 shares for $593,100.52 pursuant to a 10b5-1 trading plan adopted on 2024-11-18, reducing her non-derivative holdings from 65,134 shares to 59,634 shares. The stock currently trades at $93.01, down 17.7% from its 52-week high of $113.02, and Miller maintains derivative holdings of 72,608 stock options, preserving meaningful upside exposure. Nuvalent is unprofitable with net income of $-109,279,000.00 over its most recent full fiscal year, and her prior transactions at this ticker (5 prior sells) showed positive returns in both 30-day and 90-day windows following execution. As a scheduled transaction under a pre-arranged plan rather than a discretionary trade, this sale reflects a formulaic execution independent of current market conditions.

Chief Legal Officer of unprofitable Nuvalent executes mixed transaction: small stock purchase offset by substantial sale near current levels

Deborah Ann Miller, Chief Legal Officer at Nuvalent, executed a complex three-part transaction on the same day: a modest stock purchase of approximately 5,500 shares paired with two separate sales totaling roughly 5,500 shares for a combined value exceeding $545,000. The timing is notable—the sales occurred at prices slightly above the current trading level, suggesting Miller locked in value near recent market expectations rather than capitulating during a deep decline. However, the company remains deeply unprofitable with significant operating losses, which typically constrains executive appetite for equity accumulation. The overall pattern reads less as insider conviction and more as routine rebalancing by an officer managing tax obligations or diversification needs, especially given that the buy and sell volumes nearly offset each other on the same date.

Chief Legal Officer Deborah Miller sold 5,500 NUVL shares for $542,991.35 at blended average $98.73; holds 59,634 post-trade as stock down -13.6% from 52-week high.

Chief Legal Officer Deborah Ann Miller executed three separate sales on 2026-03-26 totaling 5,500 shares for $542,991.35 at blended average $98.73, representing an 8.4% reduction in her holdings to 59,634 shares. The transaction occurred as NUVL trades at $96.72, down 5.1% over 30 days and 13.6% from its 52-week high of $111.99, while the company reported a net loss of $122.4M over its most recent full fiscal year. Her prior four trades at NUVL over the past two months have all experienced negative 30-day returns (-5.8%, -7.0%, -6.5%, -8.8%, -8.5%), establishing a pattern of selling into sustained price declines at this ticker.

CLO Deborah Ann Miller sold 5,500 shares at blended avg $103.05 (totaling $566.8K) on 2026-02-26; stock now at $101.29, down 1.6% in 30 days.

Miller, Chief Legal Officer, executed 3 separate sales totaling 5,500 shares for $566,787.54, reducing her holdings by 8.4% from 65,134 shares to 59,634 shares post-transaction. The transaction occurred at an average price of $103.05, while the current price is $101.29, placing the stock -1.6% over 30 days and -3.5% over 90 days from transaction date. Her recent same-ticker history shows 5 prior sells at NUVL over late January 2026, with mixed near-term outcomes (ranging from +4.3% to -8.8% at 30 days), though no 90-day outcomes are yet measurable on those trades. The company reported a net loss of $-122,437,000.00 on a $317.0M market capitalization, indicating material financial distress that may provide context for ongoing insider activity.

CLO Miller sells 15,000 NUVL shares for $1,652,176 across 2 trades; retains 59.6K shares.

Deborah Ann Miller, Chief Legal Officer at Nuvalent, executed 2 separate sales totaling 15,000 shares (15.0K shares) for $1,652,176.00 ($1.7M) at an average of $110.15 per share on January 21-22, 2026. This represents a -20.1% reduction in her post-transaction holdings to 59,634 shares (59.6K shares). The company is currently unprofitable with net income of $-122,437,000.00 ($-122.4M) for its most recent full fiscal year, and the stock is -5.0% from its 52-week high of $111.99. The timing of this sale near the 52-week peak warrants attention, though the CLO retained substantial holdings, indicating incomplete divestment. With 5 prior NUVL-specific sales in early January 2026 outcomes not yet measurable at 90 days, a pattern of regular insider sales at this ticker has emerged, though this does not constitute a coordinated multi-executive event.

CLO Deborah Ann Miller sold 6,952 shares across 7 transactions for $676,157.59 on Jan 5–6, reducing stake by 10.4%

Miller Deborah Ann (Chief Legal Officer) executed 7 separate sales totaling 6,952 shares for $676,157.59 on January 5–6, 2026, at a blended average price of $97.26. The current stock price of $106.82 sits at -2.8% from the 52-week high and +21.4% over the past 90 days, reflecting recent momentum. Miller's post-transaction holdings of 59,634 shares represent a -10.4% reduction from her pre-transaction stake of 66,586 shares. Her cross-ticker track record shows 20 prior sells with a 90-day well-timed rate of 100.00%, though her same-ticker history at NUVL provides limited measurable outcomes (recent sales on 2026-01-02 are not yet measurable, while November 2025 sales showed modest negative 30-day returns of -5.4% and -4.5%). The company remains unprofitable with net income of $-122,437,000.00 and a market cap of $334,280,798.88, which investors should weigh against the stock's recent price gains when interpreting the significance of this executive sale.

CLO Deborah Ann Miller sold 10,000 shares (10.0K) for $1,005,114.30 at blended $100.51; stock now at $97.94 amid unprofitable fundamentals

Miller executed three separate sales totaling 10,000 shares for $1,005,114.30 on 2026-01-02 at prices ranging from $100.03 to $101.47, reducing her stake by 16.9% to 49.1K shares remaining. The transaction occurred near the stock's 52-week high of $109.86 (currently $97.94, down 10.8% from peak and 10.6% over 30 days). The company reported negative full-year net income of $-122,437,000.00 against a market cap of $306,491,868.96, indicating material unprofitability. Miller's cross-ticker track record shows a 90-day well-timed rate of 100.00% across 20 prior sells with an average 90-day return of -11.7%, though her five prior trades at NUVL have not yet generated measurable outcomes at the 90-day horizon. The sale's proximity to the 52-week high coupled with deteriorating financial fundamentals warrants examination of whether the transaction reflects timing relative to known operational or financial developments.

CLO Deborah Ann Miller sells 24,200 shares (33% of holdings) at $105.50 avg; stock near 52-week high after 45.5% 90-day surge

Miller executed three separate sales on 2025-11-17 totaling 24,200 shares for $2,552,998.98, reducing her NUVL holdings from 73.3K to 49.1K shares (a 33% reduction). The sales occurred at prices ranging from $105.16 to $107.04, with a blended average of $105.50, in an environment where the stock is currently trading at $107.13—within 0.8% of its 52-week high of $108.00 and following a +45.5% gain over the prior 90 days and +9.4% over the prior 30 days. This sale represents a substantial position reduction by the Chief Legal Officer at a time when the stock has appreciated significantly and is trading near recent peak levels. The timing of the transaction warrants investor attention given the concentrated nature of the divestiture and the stock's elevated valuation relative to its recent range.

CLO Deborah Miller sold 21,800 shares at blended avg $103.16 on 2025-10-30 for $2.2M, reducing stake 30.8%.

Chief Legal Officer Deborah Ann Miller executed 8 separate sales totaling 21,800 shares (21.8K shares) for $2,248,943.44 ($2.2M) at prices ranging from $96.65 to $104.78, reducing her post-transaction holdings to 49,086 shares from 70,886 shares—a 30.8% reduction. The timing of this large disposition is noteworthy: the sales occurred during a 20.3% 30-day rally and 27.7% 90-day rally, with the transaction prices ($103.16 blended) slightly above the 52-week low but below the 52-week high of $102.97 currently appearing in prior price action. The company remains unprofitable with net income of $-122,437,000.00 ($-122.4M), and the executive's same-ticker sales history shows mixed results—the 2024-09-16 sale showed a -14.8% 90d return, indicating one well-timed exit, though recent sales from 2025-10-15 and 2025-10-16 lack measurable outcomes. This substantial reduction in holdings by a senior legal officer amid negative fundamentals warrants scrutiny.

Chief Legal Officer sold 28,000 shares for $2.5M in 4 transactions at $89.98–$92.50; 36.3% holdings reduction at unprofitable biotech.

Miller sold 28,000 shares (28.0K shares) for $2,540,289.73 ($2.5M) over two days, reducing her stake by 36.3% from 77,086 to 49,086 shares. The timing is notable: her prior 5 trades at NUVL all showed negative 90-day returns (ranging from -8.4% to -13.2%), and all 5 were well-timed at the 90-day mark, suggesting a pattern of selling before declines. The company reported a net loss of $-99,653,000.00 ($-99.7M) in its most recent fiscal year and trades at a $289.5M market cap, placing it in a financially stressed position. While the stock has rallied 17.6% in the past 30 days and currently trades at $92.52 (near her blended average of $90.72), her historical success at timing downturns at this ticker warrants close observation of coming quarterly performance.